Skip to main content
$4.98 +0.15 (+3.11%) At close · Jul 29
Market Cap
$194.11M
Shares
38.98M

Curis Inc Earnings Call Transcripts

Every quarterly earnings call for Curis Inc (CRIS) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q1
2026-05-12
Curis Inc Q1 FY2026 Earnings Call
Positive tone TakeAim CLL proof-of-concept study TakeAim Lymphoma / PCNSL registrational study Emavusertib differentiation in CLL
Revenue
$
▼ 100% YoY
Diluted EPS
$-25.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-19
Curis Inc Q4 FY2025 Earnings Call
Confident tone CLL Proof-of-Concept Study PCNSL Registrational Study (TakeAim Lymphoma) Emavusertib Dual Pathway Mechanism
Revenue
$1.14M*
▼ 66% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Curis Inc Q3 FY2025 Earnings Call
Positive tone CLL Program Expansion AML Triplet Study (Aza-Ven + Emavusertib) PCNSL (Primary CNS Lymphoma) TakeAim Lymphoma Study
Revenue
$3.18M
▲ 8.4% YoY
Diluted EPS
$-9.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Curis Inc Q2 FY2025 Earnings Call
Confident tone TakeAim Lymphoma / PCNSL study Frontline AML triplet study CLL proof-of-concept study
Revenue
$2.75M
▲ 8% YoY
Diluted EPS
$-13.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Curis Inc Q1 FY2025 Earnings Call
Positive tone Emavusertib in PCNSL (TakeAim Lymphoma study) Emavusertib in AML Regulatory pathway / FDA and EMA engagement
Revenue
$2.38M
▲ 14.1% YoY
Diluted EPS
$-25.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Curis Inc Q4 FY2024 Earnings Call
Revenue
$3.35M*
▲ 24.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Curis Inc Q3 FY2024 Earnings Call
Positive tone PCNSL study with ibrutinib combination FDA regulatory engagement and accelerated approval TakeAim Leukemia (AML) data
Revenue
$2.93M
▲ 3.5% YoY
Diluted EPS
$-34.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-01
Curis Inc Q2 FY2024 Earnings Call
Confident tone TakeAim Leukemia study in AML TakeAim Lymphoma / PCNSL study IRAK4 mechanism and differentiation
Revenue
$2.55M
▲ 15.9% YoY
Diluted EPS
$-40.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Curis Inc Q1 FY2024 Earnings Call
Confident tone FLT3 mutation benchmark positioning Emavusertib clinical progress in AML and lymphoma Regulatory path and FDA discussions
Revenue
$2.09M
▼ 9.2% YoY
Diluted EPS
$-41.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-08
Curis Inc Q4 FY2023 Earnings Call
Confident tone Emavusertib leukemia program (AML) Solid tumor expansion (melanoma/IIT) Primary CNS lymphoma (PCNSL) program
Revenue
$2.70M*
▼ 6.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Curis Inc Q3 FY2023 Earnings Call
Revenue
$2.83M
▲ 0.3% YoY
Diluted EPS
$-42.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Curis Inc Q2 FY2023 Earnings Call
Revenue
$2.20M
▼ 8.2% YoY
Diluted EPS
$-49.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Curis Inc Q1 FY2023 Earnings Call
Revenue
$2.30M
▲ 11.7% YoY
Diluted EPS
$-47.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Curis Inc Q4 FY2022 Earnings Call
Revenue
$2.89M*
▼ 7.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Curis Inc Q3 FY2022 Earnings Call
Revenue
$2.83M
▼ 7% YoY
Diluted EPS
$-56.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Curis Inc Q2 FY2022 Earnings Call
Revenue
$2.39M
▲ 4.7% YoY
Diluted EPS
$-3.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Curis Inc Q1 FY2022 Earnings Call
Revenue
$2.06M
▼ 6% YoY
Diluted EPS
$-3.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Curis Inc Q4 FY2021 Earnings Call
Revenue
$3.13M*
▲ 3.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Curis Inc Q3 FY2021 Earnings Call
Revenue
$3.04M
▲ 10.8% YoY
Diluted EPS
$-2.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Curis Inc Q2 FY2021 Earnings Call
Revenue
$2.29M
▼ 3.1% YoY
Diluted EPS
$-2.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Curis Inc Q1 FY2021 Earnings Call
Revenue
$2.19M
▼ 19.2% YoY
Diluted EPS
$-2.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-16
Curis Inc Q4 FY2020 Earnings Call
Revenue
$3.02M
▼ 8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Curis Inc Q3 FY2020 Earnings Call
Revenue
$2.74M
▼ 4% YoY
Diluted EPS
$-2.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Curis Inc Q2 FY2020 Earnings Call
Revenue
$2.36M
▲ 12.7% YoY
Diluted EPS
$-3.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Curis Inc Q1 FY2020 Earnings Call
Revenue
$2.71M
▲ 53.3% YoY
Diluted EPS
$-5.60
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-19
Curis Inc Q4 FY2019 Earnings Call
Revenue
$3.29M
▲ 19.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 earnings calls
Key facts CIK 1108205 CUSIP 231269309 13F (30d) 3 filings 3 filers Visit website Investor relations